Apr 15 |
Redemption Date Announced for Warrants
|
Mar 25 |
Cassava Sciences: New Year, Same Game Of Smoke And Mirrors
|
Mar 25 |
Cassava Alzheimer's candidate simufilam clears phase 3 safety review
|
Mar 25 |
Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials
|
Mar 17 |
Cassava Sciences: Where Did All The Mild Alzheimer's Disease Patients Go?
|
Mar 12 |
Alzheimer's Drug Trial Results Questioned After 'Damning' FDA Inspection Report
|
Mar 12 |
Boeing, Oracle, Meta Platforms, Cassava Sciences, Tesla: Why These 5 Stocks Are On Investors' Radars Today
|
Mar 11 |
Cassava Sciences again under scrutiny over Alzheimer's drug research
|
Mar 6 |
Bullish Cassava Sciences Insiders Loaded Up On US$3.12m Of Stock
|
Mar 4 |
Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference
|